Cidara Therapeutics Statistics
Total Valuation
CDTX has a market cap or net worth of $2.57 billion. The enterprise value is $2.07 billion.
Important Dates
The next estimated earnings date is Thursday, November 6, 2025, after market close.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CDTX has 25.36 million shares outstanding. The number of shares has increased by 153.66% in one year.
| Current Share Class | 25.36M |
| Shares Outstanding | 25.36M |
| Shares Change (YoY) | +153.66% |
| Shares Change (QoQ) | +9.66% |
| Owned by Insiders (%) | 0.51% |
| Owned by Institutions (%) | 75.45% |
| Float | 18.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.71 |
| P/TBV Ratio | 5.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.45, with a Debt / Equity ratio of 0.00.
| Current Ratio | 16.45 |
| Quick Ratio | 15.86 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -37.05% and return on invested capital (ROIC) is -26.16%.
| Return on Equity (ROE) | -37.05% |
| Return on Assets (ROA) | -23.61% |
| Return on Invested Capital (ROIC) | -26.16% |
| Return on Capital Employed (ROCE) | -26.63% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.09M |
| Employee Count | 38 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +845.25% in the last 52 weeks. The beta is 1.34, so CDTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.34 |
| 52-Week Price Change | +845.25% |
| 50-Day Moving Average | 77.94 |
| 200-Day Moving Average | 41.44 |
| Relative Strength Index (RSI) | 58.88 |
| Average Volume (20 Days) | 1,267,153 |
Short Selling Information
The latest short interest is 3.05 million, so 12.01% of the outstanding shares have been sold short.
| Short Interest | 3.05M |
| Short Previous Month | 2.19M |
| Short % of Shares Out | 12.01% |
| Short % of Float | 16.22% |
| Short Ratio (days to cover) | 2.93 |
Income Statement
| Revenue | n/a |
| Gross Profit | -108.72M |
| Operating Income | -133.67M |
| Pretax Income | -117.10M |
| Net Income | -117.49M |
| EBITDA | -133.53M |
| EBIT | -133.67M |
| Earnings Per Share (EPS) | -$10.21 |
Full Income StatementBalance Sheet
The company has $510.58 million in cash and $2.33 million in debt, giving a net cash position of $508.24 million or $20.04 per share.
| Cash & Cash Equivalents | 510.58M |
| Total Debt | 2.33M |
| Net Cash | 508.24M |
| Net Cash Per Share | $20.04 |
| Equity (Book Value) | 501.17M |
| Book Value Per Share | 21.57 |
| Working Capital | 499.47M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$129.02 million and capital expenditures -$106,000, giving a free cash flow of -$129.13 million.
| Operating Cash Flow | -129.02M |
| Capital Expenditures | -106,000 |
| Free Cash Flow | -129.13M |
| FCF Per Share | -$5.09 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CDTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -153.66% |
| Shareholder Yield | -153.66% |
| Earnings Yield | -4.56% |
| FCF Yield | -5.02% |
Analyst Forecast
The average price target for CDTX is $118.50, which is 16.73% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $118.50 |
| Price Target Difference | 16.73% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | 240.71% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 24, 2024. It was a reverse split with a ratio of 1:20.
| Last Split Date | Apr 24, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
CDTX has an Altman Z-Score of 2.13 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.13 |
| Piotroski F-Score | 1 |
